Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells
通过自杀基因介导的增殖细胞消融开发更安全的基于干细胞的糖尿病疗法
基本信息
- 批准号:10482646
- 负责人:
- 金额:$ 25.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAllelesAnimalsBeta CellBiological AssayBlood GlucoseC-PeptideCDC2 geneCadaverCaringCell CycleCell Differentiation processCell LineCell ProliferationCell SurvivalCell TherapyCell TransplantationCellsDevelopmentDiabetes MellitusDiabetic mouseDoseDrug ImplantsEndocrineFDA approvedFibrous capsule of kidneyFormulationFoundationsGanciclovirGenerationsGeneticGlucoseGlucose tolerance testHealthHumanImmunocompromised HostImmunosuppressionIn VitroInsulinInsulin Infusion SystemsIslet CellIslets of LangerhansIslets of Langerhans TransplantationLeadLong-Acting InsulinMediatingMedicalMitoticModelingModificationMonitorMusOrgan DonorPancreasPancreas TransplantationPatientsPharmaceutical PreparationsPharmacologyPopulationPreparationProceduresProductionProliferatingProtocols documentationRattusRegulator GenesResidual stateRiskSafetySiteSourceStem cell transplantSystemTK GeneTechnologyTestingTherapeuticTissuesTransplantationUndifferentiatedbaseblood glucose regulationcell typecostdiabetes mellitus therapydiabetic patientdifferentiation protocolexperimental studyglucose monitorglycemic controlgraft functionhumanized mouseimmunogenicityimprovedin vivoin vivo evaluationinduced pluripotent stem cellinsulin secretioninsulin sensitivityisletmouse modelnew technologynovelphase 2 studypost-transplantregenerativesafety studystem cell therapystem cellssuicide genetissue stem cellstooltumortumorigenicvirtual
项目摘要
Project Summary/Abstract
Diabetes is an increasingly important health problem worldwide. In the 100 years since the discovery of insulin,
tremendous advances have been made in the care of diabetic patients, including long-acting insulin formulations,
insulin pumps, continuous glucose monitors, and wide array of pharmacologic agents that influence insulin
secretion and sensitivity. Despite all of these advances, a majority of diabetic patients cannot achieve currently
recommended targets for blood glucose control. Although transplantation of diabetic patients with donor-derived
pancreatic islets or intact pancreas remains a rare procedure due to limited source material, these cell-based
therapies are extremely effective in restoring blood glucose control. In order to make a cell-based therapy for
diabetes available to more patients, Regenerative Medical Solutions (RMS) has developed a proprietary protocol
for converting induced pluripotent stem cells (iPSC), a virtually unlimited cell source, into islet-like clusters of
cells that include insulin-producing beta-like cells. These cells demonstrate functionality similar to primary beta
cells both in vitro and after transplantation into diabetic mice, indicating their potential as a cell-based therapy
for diabetes. However, as will all iPSC-based therapies, safety concerns remain: the transplantation of even a
small number of proliferative cells in an iPSC-based product may result in undesired outgrowths or tumor
formation at the graft site. To address this potential risk, Implant Therapeutics has developed a novel genetically
modified iPSC line, FailSafeTM, in which the thymidine kinase gene is homozygously integrated downstream of
the essential cell cycle regulatory gene CDK1. Treatment of FailSafeTM cells with the FDA-approved drug
ganciclovir thus leads to selective elimination of actively proliferating cells. In this project, we will combine
FailSafeTM iPSC and RMS’s proprietary protocol for the production of islet-like clusters of cells to demonstrate
the potential of the combined product to produce a safer cell-based therapy for diabetes. First, we will define
optimal conditions for the ablation of proliferating cells from islet-like clusters in culture. Next, we will demonstrate
the safety and efficacy of the treated FailSafeTM clusters in a mouse model of diabetes. Together, these
experiments will lay the foundation for the development of a cell-based therapy for diabetes with an improved
safety profile compared to competing products.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DENA E COHEN其他文献
DENA E COHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DENA E COHEN', 18)}}的其他基金
Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance
评估通过局部诱导免疫耐受而无需免疫抑制的 β 细胞替代疗法组合产品
- 批准号:
10603016 - 财政年份:2022
- 资助金额:
$ 25.96万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 25.96万 - 项目类别:
Research Grant